Abstract
Neutralization assays that can measure neutralizing antibodies in serum are vital for large-scale serodiagnosis and vaccine evaluation. Here, we establish multiplexed lab-on-a-chip bioassays for testing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. Compared with enzyme-linked immunosorbent assay (ELISA), our method exhibits a low consumption of sample and reagents (10 μL), a low limit of detection (LOD: 0.08 ng/mL), a quick sample-to-answer time (about 70 min), and multiplexed ability (5 targets in each of 7 samples in one assay). We can also increase the throughput as needed. The concentrations of antibodies against RBD, D614G, N501Y, E484K, and L452R/E484Q-mutants after two doses of vaccines are 6.6 ± 3.6, 8.7 ± 4.6, 3.4 ± 2.8, 3.8 ± 2.8, and 2.8 ± 2.3 ng/mL, respectively. This suggests that neutralizing activities against N501Y, E484K, and L452R/E484Q-mutants were less effective than RBD and D614G-mutant. We performed a plaque reduction neutralization test (PRNT) for all volunteers. Compared with PRNT, our assay is fast, accurate, inexpensive, and multiplexed with multiple-sample processing ability, which is good for large-scale serodiagnosis and vaccine evaluation.
【초록키워드】 neutralizing antibody, SARS-CoV-2, Vaccine, coronavirus, Neutralizing antibodies, antibody, severe acute respiratory syndrome Coronavirus, variants, ELISA, serum, enzyme-linked immunosorbent assay, Neutralizing activity, Plaque reduction neutralization test, L452R, RBD, N501Y, neutralization test, limit of detection, D614G, E484K, target, respiratory, volunteers, PRNT, Concentration, dose, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, enzyme, reagents, neutralizing activities, throughput, bioassay, neutralization assays, reagent, plaque reduction neutralization, effective, enzyme-linked immunosorbent, performed, less, exhibit, testing antibody, 【제목키워드】 SARS-CoV-2, Testing, individual, bioassay, Multiple,